Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. It also develops and invests in stem cell and medical technology. The company was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company